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Though the genetic background of ischaemic and haemorrhagic stroke is often polygenetic or multifactorial, it can in some cases
result from a monogenic disease, particularly in young adults. Besides arteriopathies and metabolic disorders, several connective
tissue diseases can present with stroke. While some of these diseases have been recognized for decades as causes of stroke, such as
the vascular Ehlers-Danlos syndrome, others only recently came to attention as being involved in stroke pathogenesis, such as those
related to Type IV collagen. This paper discusses each of these connective tissue disorders and their relation with stroke briefly,
emphasizing the main clinical features which can lead to their diagnosis.
1. Introduction
Epidemiological studies on stroke, one of the prominent
causes of death and disability in the Western world, have
revealed a strong genetic influence in its pathogenesis, with
conventional risk factors contributing only up to 40%–
50% of stroke risk [1]. Often stroke represents a complex
polygenetic or multifactorial disease, hampering the iden-
tification of causal genes. However, in some individuals—
particularly young adults—stroke can result from a mono-
genic disorder [2, 3]. Next to arteriopathies (Cerebral
Autosomal Dominant of Autosomal Recessive Arteriopa-
thy with Stroke-like Episodes and Leucoencefalopathy—
CADASIL and CARASIL, resp.) or metabolic diseases (Fabry,
homocystinuria), several connective tissue disorders (CTD)
can involve ischaemic or haemorrhagic stroke as part of the
phenotype in young adults. Moreover, several extracellular
matrix (ECM) components have been (suggested to be)
implicated in stroke pathogenesis [4].
The connective tissue is a basic type of tissue providing
structural andmetabolic support for other tissues and organs
throughout the body. Its uniqueness, compared to other tis-
sues, lies in its composition of a diverse set of constituents—
cells, fibres, blood vessels—scattered around in an ECM.
Four types of macromolecules can be distinguished in the
ECM: collagen, elastin, glycoproteins and proteoglycans.
Heritable disorders that involve connective tissue are
among the most common genetic diseases in humans.
Their classification is not without challenge because of the
phenotypic variability within and between families which
characterizes several of these disorders. Classification also
tends to overemphasize the aetiologic diﬀerences between
severe genetic disorders that are apparent in infants or young
children and the more common diseases that appear later
in life. Yet these late-onset diseases, such as aneurysms
and stroke, can be caused or influenced by single-gene
variants. Because of the wide distribution of connective
tissues within the human body, diseases that aﬀect connective
tissue cells or ECM proteins often have systemic eﬀects.
Based on the two major constituents of the connective tissue,
collagen and elastin, these disorders can be divided into
“collagenopathies” and “elastinopathies” [5, 6].
Awareness for and recognition of such connective tissue
disorders has a broad relevance as their identification has
implications not only for counselling, recurrence risk and
risk for associated manifestations, but also for management
and prognosis. This paper attempts to present a compre-
hensive review of the most important connective tissue
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diseases to consider when confronted with stroke in young
adults. Also some promising candidate genes encoding ECM
proteins will be discussed briefly.
2. Disorders Affecting the Collagens
Collagens are triple helical proteins formed when three
polypeptide chains, called alpha chains, wind around each
other to form a collagen molecule. The collagen superfamily
of proteins is a major component of the ECM and contains
the most abundant proteins in the body which are classified
into 29 collagen types [7]. A wide spectrum of diseases has
been associated with the collagens, caused by mutations in at
least 27 diﬀerent collagen-associated genes [5]. Of them, the
Ehlers-Danlos syndromes, osteogenesis imperfecta, autoso-
mal dominant polycystic kidney disease and collagen Type
IV can be related to stroke.
2.1. The Ehlers Danlos Syndrome. The Ehlers-Danlos syn-
drome (EDS) is a clinically and genetically heterogeneous
group of connective tissue disorders, aﬀecting approximately
1 in 5000 individuals [8, 9]. It can be catagorized into
several types, based on the phenotypical and molecular
characteristics (Table 1).
The classic and hypermobility type are characterised
by various expression of joint hypermobility and related
complications, easy bruising and atrophic scarring. In con-
trast, the vascular type of EDS (Type IV) presents with a
distinct tissue fragility of the vasculature, colon and uterus,
while hypermobility and bruising are less prominent [8–
10]. Particularly in the latter, autosomal dominant form,
haemorrhagic or ischaemic stroke may occur at young age
[11].
EDS Type IV (OMIMno. 130050) results frommutations
in the COL3A1 gene, encoding Type III procollagen (chrom.
2q31); the mutation spectrum is broad with novel mutations
being a common finding (approximately 50%). The mutant
Type III collagen has reduced strength, elasticity and healing
properties as well as defective integration into the normal
ECM, resulting in the typical EDS IV phenotype [10].
This encompasses a typical facial appearance (thin nose
and lips, sunken cheeks, small chin), thin skin and fragile
arteries and intestines which tend to rupture (Figure 1) [10].
Neurovascular complications are seen in approximately 10%
of patients and include intracerebral aneurysms of large
and medium-sized arteries and (spontaneous) dissection of
carotid and vertebral arteries, often without prior dilatation
[12–17]. Aneurysms typically develop in the cavernous
sinus or just as the carotid artery emerges from the sinus
and bilateral carotid aneurysms have been reported [18].
These may be associated with other complications such
as spontaneous carotid-cavernous fistulas [18–20]. Also,
arterial tortuosity, ectasia and dilatation or stenosis have
been described in EDS Type IV [21].
The diagnosis of EDS Type IV is based on clinical
examination, biochemical analysis of the collagens on cul-
tured skin fibroblasts and molecular analysis of the COL3A1
gene [10, 16]. No current aetiological treatment is available
and management focuses on counselling and symptomatic
control. In this respect, management dilemmas may arise
when confronted with a vascular EDS patient, as the extreme
tissue fragility makes interventional or surgical procedures
to medicate, for example, aneurysms less obvious, as they are
associated with a tremendous risk for morbidity (especially
haemorrhages) and mortality [18, 22, 23].
2.2. Type IV Collagen-Related Small Vessel Disease. Type
IV collagen comprises a family of triple helical isoforms
consisting of at least six genetically distinct chains with
tissue-specific distribution. The heterotrimer isoform con-
sisting of one alpha-1 and two alpha-2 chains, encoded
by the COL4A1 gene (chrom. 13q34) and COL4A2 gene
(chrom. 13q34), respectively, is located a.o. in the basement
membrane of arteries throughout the body [24]. Mutations
in COL4A1 have already been established in autosomal
dominant porencephaly and infantile hemiparesis [25, 26].
A Col4a1 knock-out mouse model predisposes newborn and
adultmice to intracerebral haemorrhage, with predominance
in the basal ganglia. In addition, these knock-out mice
showed retinal tortuosity together with glomerular basement
membrane defects [27].
Recently, COL4A1 gene mutations have been recognized
as the cause of small vessel disease in adults presenting with
either ischaemic stroke or intracerebral haemorrhage [28–
30]. The mean age of onset was 36 years (range: 14–49 yrs.).
In a majority of the young adults, small vessel disease was the
presenting symptom. Other associated features may include
previous history of infantile hemiparesis, seizures, cognitive
impairment and a familial history of migraine [27, 31]. As in
mice, these patients often have retinal arteriolar tortuosity
in fundo [27, 31]. Also renal and muscular involvement
has been documented. The association of a hereditary
angiopathy, nephropathy, aneurysm and muscle cramps has
been defined as the HANAC syndrome [32, 33]. These
patients were shown to have microvascular brain disease and
single or multiple intracranial aneurysms (primarily on the
carotid siphon), together with retinal arteriolar tortuosity,
cystic renal disease with thickened renal basement mem-
brane featuring hematuria and muscle cramps with elevated
creatinine kinase, possibly due to transient ischaemia or
microhaemorrhages [32, 33].
The diagnosis of collagen Type IV -associated stroke can
be made on brain imaging, featuring frequent leukoaraio-
sis, subcortical microbleeds, lacunar infarction and dilated
perivascular spaces in conjunction with systemic features
or positive familial history [27]. Additional investigations
should include a funduscopic examination and renal evalu-
ation. A skin biopsy has been suggested a useful examina-
tion in HANAC syndrome, with significant ultrastructural
anomalies including replication of the lamina densa, altered
dermal arteriolar wall morphology and dissociation of
vascular smooth muscle cells [33]. No data are available
on ultrastructural changes of the skin in nonHANAC
COL4A1 patients. Molecular confirmation can be obtained
byCOL4A1 sequencing. So far, only missense mutations have
been reported involving highly conserved glycine residues in
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Table 1: Villefranche classification of Ehlers-Danlos syndrome (1998).
Type Inheritance Gene(s) Phenotype
Classic EDS (Types I/II) AD
COL5A1,
COL5A2
Hyperelastic, soft skin, atrophic scars, easy bruising, joint hyperlaxity
Hypermobility EDS (Type III) AD Unknown Gross joint hyperlaxity, mild atrophic scarring and easy bruising
Vascular EDS (Type IV) AD COL3A1
Typical facial gestalt, skin fragility, extreme vascular fragility, rupture
of uterus and colon
Kyphoscoliosis EDS (Type VI) AR PLOD
Marfanoid habitus, hypotonia, kyphoscoliosis, ocular complications
+ features of Type I EDS
Arthrochalasis EDS
(Types VIIA and B)
AD
COl1A1,
COL1A2
Severe joint hyperlaxity, congenital bilateral hip dyslocation, easy
bruising, scoliosis, hypotonia
Dermatosparaxis EDS
(Type VII C)
AR
Procollagen,
N-peptidase
Severe skin fragility, sagging redundant skin, excessive bruising
AD: autosomal dominant; AR: autosomal recessive.
a triple helical domain of the gene. It is currently unclear
whether a solid genotype-phenotype correlation is present,
though it has been suggested that themutation site may relate
to the phenotype, as the HANAC-associated mutations are
closely related [28].
Management of individuals with a COL4A1 mutation
is symptomatic. As cerebral haemorrhage often occurred
following trauma or anticoagulant therapy, both in mice and
humans, the prevention of trauma and avoidance of risk
factors for bleeding may decrease the risk for (repetitive)
haemorrhaging in these patients [27].
2.3. Osteogenesis Imperfecta. Osteogenesis imperfecta (OI)
is a heterogeneous group of heritable connective tissue
disorders characterised by fragile and brittle bones, blue
sclerae, dental malformations, deafness and hyperextensible
ligaments (Figure 2) [34, 35]. Diﬀerent subtypes can be
recognized with a broad range in severity, from mild to lethal
(Sillence classification, Table 2) [36]. The inheritance modus
of OI includes both autosomal dominant and recessive
forms, caused by mutations in diﬀerent genes (COL1A1,
COL1A2, LEPRE1, CRTAP, FKBP10, PPIB) [34, 35, 37–39].
Most patients have a mutation in one of the genes enco-
ding Type I collagen, COL1A1 (chrom. 17q21.31-q22) and
COL1A2 (chrom. 7q22.1). Type I collagen, a heterotrimer
similar to Type IV collagen, has a broad tissue distribution,
including bone and vessel wall [34, 35].
COL1A1 and COL1A2 mutations will induce a dimi-
nished or aberrant production of osseous and vascular Type
I collagen which in return will lead to diminished resistance
of bone against repetitive stress as well as to the reported
aortic dissection or ulnar artery aneurysms [37, 40, 41].
In the fully developed brain, Type I collagen can be found
predominantly in and around large arteries [42]. Details
on neurovascular involvement in OI are however scarce.
The complications which have been reported, although
infrequent, include ruptured cerebral aneurysm associated
with fenestrated vertebral arteries, moyamoya-like disease,
carotid-cavernous fistula, cervical and vertebral artery dis-
section [43–45].
The diagnosis of OI is based on familial history and a
history of fractures, clinical and radiological examination,
biochemical analysis of the collagens andmolecular sequenc-
ing of the OI-associated genes [34, 35].
The objective of treatment in OI is maximal mobility
and functionality via physiotherapy and revalidation. Intra-
venous bisphosphonates have also been generally accepted as
part of the treatment with positive eﬀect on bone density and
cortical thickness [34, 35, 46].
2.4. Autosomal Dominant Polycystic Kidney Disease. Autoso-
mal dominant polycystic kidney disease (ADPKD, OMIM#
613095, 173900) is an adult onset multisystem disorder
characterised by bilateral renal cysts, cystic changes in other
organs such as liver or pancreas, and vascular abnormalities,
including dilatation and dissection of the aorta and intracra-
nial aneurysms [47]. Its prevalence at birth is between 1 : 400
and 1 : 1000. There is evidence that ADPKD is a collagen
matrix disease, as histological evaluation of resected kid-
ney specimens showed dilated and tortuous parenchymous
blood vessels as well as excessive and oedematous collagenous
tissue. The weak and excessive collagen is suggested to play a
central role in the pathogenesis of diﬀerent manifestations
of ADPKD [48]. ADPKD is caused by mutations in the
PKD1 (chrom. 16p13.3–p13.12) or PKD2 gene (chrom.
4q21-q23), encoding polycystin 1 and 2, respectively, [47].
Though clinical manifestations of both types overlap, PKD1
is associated with more severe disease than PKD2, with larger
kidneys and earlier onset of renal failure [49]. Polycystin 1 is
thought to be a membrane protein, involved in cell-to-cell
or cell-matrix interactions, whereas polycystin 2 is thought
to be a channel protein. The mechanisms contributing to
cystogenesis are complex and are beyond the purpose of this
paper [50].
The most frequent neurovascular complication of
ADPKD is intracranial aneurysms, occurring in approxi-
mately 10% of patients, with a higher prevalence (22%)
in those individuals with a positive familial history of
intracranial haemorrhage [51, 52]. Most of these aneurysms
are asymptomatic. However, the mean age of rupture is
considerably lower, being 39 years in ADPKD patients versus
51 years in the general population. At the time of rupture,
most patients still have normal renal function, though
hypertension is often noted [53].
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Figure 1: Clinical and biochemical characteristics of the vascular Ehlers-Danlos syndrome. Typical facial features with diminished
subcutaneous fat, thin nose and lips (a, b), acrogeria (c) and easy bruising (d). Biochemical analysis of the collagens reveals a diminished
amoun of collagen Type III (e).
For the diagnosis of ADPKD, renal ultrasonography is
commonly used with highly predictive ultrasound diagnostic
criteria being available. Molecular confirmation can be done
using DNA linkage or gene-based direct sequencing. Screen-
ing should be performed in aﬀected patients for extrarenal
manifestations of the disease. Particularly in those patients
with a positive family history of intracranial aneurysms, an
MRI angiography should be included [54].
Management is directed toward reducing morbidity and
mortality from the renal and extrarenal complications of
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Figure 2: Clinical features of osteogenesis imperfecta. Osteopenia and multiple fractures (a), bone deformities (b) and blue sclerae (c).
the disease and includes antihypertensive medication, cyst
decompression, control of hyperlipidemia and dietary pro-
tein restriction [51, 55, 56]. Symptomatic cerebral aneurysms
are usually treated by surgical clipping. Asymptomatic
aneurysms are closely followed at yearly interval; controversy
exists whether surgery is required at a diameter of more than
5mm or 10mm [57]. The main-stay therapy for ruptured
or symptomatic intracranial aneurysm is surgical clipping.
In some cases, endovascular treatment (coiling) may be
indicated [51].
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Table 2: Silence classification of osteogenesis imperfecta.
Type Inheritance Gene(s) Phenotype
OI Type I AD COL1A1
Fractures, osteopenia, blue sclerae, severe hearing loss, dentinogenesis
imperfecta in some
OI Type II AD COl1A1,
COL1A2
Multiple fractures, severe osteopenia and bone deformation, short
stature, blue sclerae
OI Type III AD/AR COl1A1,
COL1A2
Triangular face, severe scoliosis, fractures, osteopenia and bone
deformities, short stature, bleu sclerae, hearing loss, dentinogenesis
imperfecta in some
OI Type IV AD COl1A1,
COL1A2
Fractures, osteopenia and bone deformities, hearing impairment,
dentinogenesis imperfecta, short stature in some
OI Type V AD Unknown
Fractures, osteopenia and bone deformities, hearing impairment,
dentinogenesis imperfecta, short stature in some, often luxation of
head of radial bone
OI Type VI ? FKBP10
Multiple fractures, osteopenia and bone deformities, hearing
impairment, short stature in some, accumulation of osteoid in bone
OI Type VII AR CRTAP
Multiple fractures, osteopenia and bone deformation, blue sclerae,
rhizomelia, coxa vara
OI Type VIII AR LEPRE1
Multiple fractures, severe osteopenia and bone deformation, short
stature, blue sclerae in some
AD: autosomal dominant; AR: autosomal recessive. Characteristics which may be of value in discriminating the subtypes are marked in italics.
3. Disorders Affecting Elastic Fibres
The elastic fibre system forms a network responsible for
the resilience and elasticity of various tissues. It consists
of interconnecting fibres of varying diameter, containing
two distinct components: elastin, a well-characterised con-
nective tissue protein and elastin-associated microfibrils,
the components of which include fibrillin, a microfibril-
associated glycoprotein. The biology of elastic fibres is
complex because of its multiple associated molecules, tightly
regulated developmental pattern of deposition, multi-step
assembly, unique elastomeric properties and influence on
cell phenotype. Several hallmark connective tissue disorders,
such as Marfan syndrome or pseudoxanthoma elasticum,
are caused by abnormalities of the elastic fibres, and can be
related to stroke.
3.1. Pseudoxanthoma Elasticum and the PXE-Like Syndrome.
Pseudoxanthoma elasticum (PXE, OMIM# 264800) is an
autosomal recessive disorder characterised by skin, ocular
and cardiovascular symptoms resulting from ectopic min-
eralization and fragmentation of elastic fibres [58, 59]. It is
caused by mutations in the ABCC6 gene (chrom. 16p13.1),
encoding an ATP-binding transporter protein, the substrate
and (patho)physiological role of which remain currently
unknown [60]. Recent insights have revealed deficient
vitamin K-dependent calcification inhibitors—due to low
serum vitamin K in PXE patients—to induce the ectopic
mineralization of elastic fibres [61]. The skin phenotype
exists of yellowish papules of degraded elastic fibres in the
flexural areas of the body, coalescing into larger plaques,
sometimes associated with the presence of additional skin
folds (Figure 3) [58, 59]. The PXE retinopathy, based on
elastic fibre abnormalities in the Bruch’s membrane, involves
angioid streaks and subretinal neovascularisation, resulting
in retinal haemorrhages and vision loss (Figure 3) [58,
59]. Cardiovascular complications exist of coronary and
peripheral artery disease (hypertension, myocardial infarc-
tion, claudication), gastrointestinal haemorrhage as well as
predominantly ischaemic stroke. The latter was found in
15% of PXE patients, with a mean age of onset of 49 years
[58, 59]. Intracerebral haemorrhage has been described in
rare cases of PXE [62].
Heterozygous carriers of 1 ABCC6 mutation do not tend
to develop symptomatic skin or ocular manifestations of
PXE, but do have an increased cardiovascular risk [59, 63–
65]. In addition, it has been shown that a significantly higher
proportion of heterozygous ABCC6 carriers can be found
in an ischaemic stroke population compared to normal
controls, suggesting it to be a molecular risk factor for
ischaemic stroke (Vanakker et al., unpublished data).
In 2007, we described a novel autosomal recessive PXE-
like syndrome (OMIM# 610842), characterised by a severe
cutaneous phenotype with thick and redundant skin folds
beyond the flexural areas, a mild retinopathy and a deficiency
of the vitamin K-dependent coagulation factors (Figure 4)
[66]. This disease was shown to be caused bymutations in the
GGCX gene, encoding a gamma-carboxylase which performs
an essential posttranslational modification step of several
vitamin K-dependent proteins, such as clotting factors and
mineralization inhibitors. In two of the originally described
patients, cerebral aneurysms were present, one of which had
recurrent cerebral aneurysms [66]. It is however at present
unclear whether these are actually part of the phenotype or a
coincidental finding.
The diagnosis of PXE should be thought of in the
presence of skin or ocular symptoms and can be confirmed
by skin biopsy and molecular sequencing of the ABCC6 gene
[59]. Depending on the phenotype, including cutis laxa and
a clotting deficiency, GGCX sequencing may be appropriate
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Figure 3: Cutaneous and ophthalmological symptoms of PXE. Plaques of papules in the neck region (a), increased skin laxity (b) and
mucosal involvement with yeloowish pattern on the inner lip (c). The retinopathy consists of peau d’orange (d, oval), angioid streaks (d,
arrowed), retinal hemorrhaging (e). In some cases calcifications of Bruch’s membrane can be seen as comets or comet tails (f, arrowed).
[66]. In view of the number of heterozygotes in a general
ischaemic stroke population, ABCC6 analysis is suggested as
a diagnostic option in young individuals suﬀering ischaemic
stroke, with no significant conventional risk factors.
In the absence of an aetiological therapy, management of
PXE is focussed on the prevention and treatment of com-
plications [59]. Anti-VEGF antibodies, such as bevacuzimab
or ranibizumab, are used to treat ocular complications such
as neovascularisation, with significant success [67]. Other
aspects of management include cardiovascular prevention
measures and avoidance of anticoagulants, nonsteroidal
antiinflammatory drugs and head trauma [59]. Particularly
the relative contra-indication for anticoagulant therapy in
PXE patients, because of the ocular and gastrointestinal
bleeding diathesis, can create a therapeutic dilemma for
which no ideal solution exists. An individual assessment
should be made in each patient of the benefits and risks of
starting such therapy, taking into account the specifics of the
patients’ phenotype.
3.2. Marfan Syndrome. The Marfan syndrome (MFS,
OMIM# 154700) is an autosomal dominant multisys-
temic disorder characterised by skeletal (marfanoid habi-
tus with tall stature, arachnodactyly, pectus deformity
and joint hypermobility), ophthalmological (ectopia lentis,
myopia) and cardiovascular symptoms (aortic root dilata-
tion) (Figure 5) [68]. It is caused by mutations in the FBN1
gene (chrom. 15q21.1), encoding the ECM protein fibrillin 1,
expressed in the heart and elastic arteries [69]. In about 25%
of probands, this mutation occurs de novo [69].
The most frequent neurovascular complication in MFS
is an extension of an aortic dissection into the common
carotid artery [70]. Spontaneous dissections limited to the
common or internal carotid artery have also been reported
[71]. In a large retrospective study, Wityk et al. described
a neurovascular event in approximately 3.5 percent of
Marfan patients, most of which were TIAs (65%), cerebral
infarctions (most often cardioembolic, 10%), spinal cord
infarctions (10%), subdural haematomas (10%) or spinal
subarachnoid haemorrhage (5%) [72]. A conclusive relation-
ship between MFS and intracranial aneurysms has not been
established [73, 74].
The clinical diagnosis of Marfan syndrome can be made
based on the revised Ghent nosology criteria and confirmed
molecularly by analysis of the FBN1 gene [75]. Treatment of
the MFS involves the use of beta-blockade and angiotensin-
converting enzyme inhibition therapy to achieve reduction
of hemodynamic stress and delay the progression of arterial
dilatation. When critical dilatation of the aorta occurs, with
significant risk for aortic dissection or rupture, aortic root
replacement surgery is performed [76, 77].
3.3. Loeys-Dietz Syndrome. Loeys-Dietz syndrome (LDS,
OMIM# 608967, 609192, 610168, 610380) is an autosomal
dominant disease caused by mutations in the transforming
growth factor beta receptor 1 or 2 (TGFBR1 and TGFBR2,
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Figure 4: Clinical symptoms of the PXE-like syndrome. Severe cutis laxa-like skin folds beyond the flexural areas (a). A mild retinopathy
with minimal angioid streaks (b, arrowed).
chrom. 9q22 and 3p22, resp.), altering the transmission
of subcellular TGF-β signal, mediated by increased acti-
vation of Smad2 [78]. Common clinical features include
aortic and arterial aneurysms or dissections and skeletal
manifestations resembling Marfan syndrome (pectus defor-
mity, arachnodactyly, joint laxity). Seventy-five percent of
patients have LDS Type I with craniofacial features including
hypertelorism and cleft palate or bifid uvula (Figure 6) [78,
79]. LDS Type II resembles vascular EDS, with cutaneous
manifestations such as easy bruising and atrophic scars.
In contrast with Marfan syndrome, generalised arterial
tortuosity and aneurysms of other arteries besides the aorta
have been noted. Tortuosity was most frequently seen in head
and neck vessels [78, 79]. In LDS Type I and II, aneurysmal
changes of the vertebral and head arteries were reported
[80, 81]. In LDS Type I, 11% of patients had aneurysms of
arteries in the head and neck, compared to 7% in LDS Type
II [79]. Importantly, these vascular abnormalities tend to
manifest at a younger age, with a more aggressive evolution
which can be observed by dissection or rupture at a vessel
diameter which is not predictive of such an event. This
aggressive nature is also reflected in a mean age of death of
LDS patients of 37 years, with cerebral bleeding as the third
leading cause of demise after thoracic and abdominal aortic
dissection [78, 79].
The diagnosis of LDS is based on the clinical charac-
teristics and can be confirmed by mutation analysis of the
TGFBR1 and TGFBR2 gene [78, 79]. As the natural history
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Figure 5: The Marfan syndrome. Patients present with skeletal findings such as pectus excavatum (a), lens luxation (b) and aortic root
dilatation (c).
of LDS diﬀers from that of other CTD, management is
individualised and involves measures as described for the
Marfan syndrome but with an even more rigorous followup
and option of surgical repair of aortic dilatation at a smaller
diameter and at an earlier age compared to Marfan patients
[78, 79, 82].
3.4. Bicommisural Aortic Valve with Ascending Aortic Aneu-
rysm. Bicommisural (bicuspid) aortic valve with ascending
aortic aneurysm (BAV, OMIM# 109730) is considered a
separate entity characterised by an aortic valve with 2
rather than 3 leaflets, which can be associated with life-
threatening aneurysm or dissection of the aorta (Figure 7)
[83, 84]. It is inherited in an autosomal dominant fashion
with reduced penetrance, especially in females [85]. BAV is
thought to be genetically heterogeneous, with at present only
one gene identified, the NOTCH1 gene, on chrom. 9q34.3
[86]. NOTCH1 is a signalling and transcription regulator
which causes a spectrum of developmental nonsyndromic
aortic valve anomalies and severe valve calcification [87].
BAV is a common congenital heart defect, aﬀecting 1 to 2%
of the population. Though it was a long-standing belief that
the aortic changes were due to postvalvular hemodynamic
changes, it has now become clear that they are primarily
related to the underlying arteriopathy, thus making BAV a
generalised CTD [83, 84].
The BAV arteriopathy does not seem to be confined
to the thoracic aorta, as spontaneous dissections of the
cervical and intracranial arteries have been reported [88–90].
Recently, Schievink et al. reported an increased frequency of
aneurysms of the intracranial carotid and cerebral arteries
among patients with BAV, levelling up to 10% compared to
1% in controls [91].
The diagnosis of BAV is made via heart auscultation and
confirmed by cross-sectional and doppler echocardiography
[83, 84]. Molecular analysis of the NOTCH1 gene may be
helpful in familial screening, though BAV is undoubtedly
genetic heterogeneous [85]. Management includes regular
clinical followup, endocarditis prophylaxis and surgical
intervention if necessary. No formal screening protocol has
been established for BAV patients to evaluate the presence
of intracranial aneurysms. Further studies are needed to
evaluate the usefulness of sequential MRI-angiography in
this patient population [92]. First degree relatives of a patient
should be oﬀered screening for BAV.
3.5. Arterial Tortuosity Syndrome. Arterial tortuosity syn-
drome (ATS, OMIM# 208050) is an autosomal recessive
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Figure 6: Features of the Loeys-Dietz syndrome Type I. Patients present a marfanoid habitus and hypertelorism (a, c), aortic dilatation (c)
and a bifid uvula (d).
connective tissue disorder, characterised by arachnodactyly,
joint and skin laxity and widespread arterial involvement
with elongation, tortuosity and aneurysm of the medium-
sized and large arteries [93]. Facial characteristics include
a long slender face with sagging cheeks, beaked nose, thin
skin, large ears and high-arched palate (Figure 8) [93, 94].
It is caused by mutations in the SLC2A10 gene, encoding
the facilitative glucose transporter GLUT10 [95]. Deficiency
of GLUT10 is associated with upregulation of the TGF-β
pathway in the arterial wall, similar to LDS, resulting in
disruption of elastic fibres and fragmentation of the internal
elastic membrane [95, 96].
Ischaemic stroke has been described in four cases of
ATS, all of which were in young adults. The mechanism
by which ATS leads to stroke has not been established but
may involve alterations of the endothelial surface leading to
arterial thrombosis, arterial stenosis evolving to occlusion
and infarction or dissection of an aﬀected vessel [94, 97].
The diagnosis of ATS is made based on clinical examina-
tion and bloodvessel imaging by means of ultrasound and
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Figure 7: Echocardiographic image of a bicuspid aortic valve.
MRI-angiography to demonstrate arterial tortuosity. The
diagnosis can then by confirmed by analysis of the SLC2A10
gene. Currently, no aetiological treatment exists for ATS
and management is focussed on prevention, detection and
treatment of the complications [93, 94].
3.6. Supravalvular Aortic Stenosis. Supravalvular aortic
stenosis (SVAS, OMIM# 185500) may occur as an autosomal
dominant isolated disease or as part of a complex devel-
opmental disorder, the Williams-Beuren syndrome (WBS)
[98, 99]. Clinical and structural characteristics of SVAS are
however identical in both groups. Isolated SVAS is caused by
mutations in the elastin gene (ELN, chrom. 7q11.2), leading
to disorganization of the lamellar architecture of the tunica
media, irregular elastic fibres and smooth muscle cell hyper-
trophy [100]. Patients may present with dyspnoea, angina
and syncope due to a variable degree of left ventricular
outflow tract obstruction [98]. In addition to the aorta, other
major arteries, including carotid and cerebral vessels, may
also be aﬀected by narrowing in patients with SVAS, leading
to susceptibility to stroke from childhood on [101].
As part of the WBS, an autosomal dominant syn-
drome featuring besides the cardiovascular and connective
tissue problems also neurobehavioural, facial, metabolic
and growth abnormalities, it is associated with a 1.5–2MB
microdeletion on chrom. 7q11.2 [99]. SVAS can be observed
in 70% of patients. Arterial narrowing may be isolated or
can occur simultaneously at diﬀerent locations, including
the intracranial vessels. WBS patients can suﬀer ischaemic
stroke in the presence or absence of stenosis of the cerebral
vasculature [102]. Prognosis may be compromised if intra-
cerebral haemorrhage occurs simultaneously [103]. Besides
SVAS, also hypertension due to renal artery involvement may
be a contributory factor to stroke in WBS.
Diagnosis of SVAS is made on echocardiography. Treat-
ment consists of surgical patch grafting of the stenotic
region of the aorta. Less invasive procedures, such as balloon
angioplasty or stenting, have been successful but carry a
higher risk for rupture, aneurysm or restenosis [99].
(a)
(b)
Figure 8: Patient characteristics of the Arterial Tortuosity Syn-
drome. Longslender face with sagging cheeks and large ears (a).
Marked arterial tortuosity (b).
4. Disorders with Generalised Connective
Tissue Involvement
4.1. Spontaneous Cervical Artery Dissection. Spontaneous
cervical artery dissection (SCAD, OMIM# 147820) is an
important cause of ischaemic stroke in young patients [104].
Though some CTD, such as osteogenesis imperfecta or the
classical and vascular form of EDS, predispose for SCAD,
most patients do not feature other symptoms of CTD
[105–107]. Still, ultrastructural analysis revealed mild but
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reproducible disruption of connective tissue morphology,
with involvement of either collagen or elastic fibres or both
[108]. Its pathogenesis being unclear, several candidate genes
and loci have been proposed, many of which are involved in
the biosynthesis of the ECM.However, several genes involved
in important CTD, such as COL3A1, COL5A1, COL5A2 and
ABCC6 have been excluded in sporadic SCAD patients [109–
112]. Large studies, such as the European CADISP (Cervical
Artery Dissection and Ischaemic Stroke Patients) study, are
currently ongoing to unravel the genetic background of
SCAD [113].
In a minority of patients, a positive familial history
is present, suggesting an autosomal dominant inheritance
pattern [114, 115]. As most patients do not have such
a family history, it is proposed that the penetrance of
the genetic predisposition of SCAD is low, meaning that
the connective tissue aberration is not a suﬃcient cause
for SCAD. Other constitutional and environmental factors
which have been identified in SCAD patients and may influ-
ence the phenotype include infection and mild hyperhomo-
cysteinemia [116].
The diagnosis of SCAD being a clinical one, the probable
heterogeneous genetic aetiology of the disorder does not
allow specific diagnostic molecular analysis in patients at this
time if classic CTD such as EDS, OI or Marfan syndrome
have been clinically excluded [117]. It must be noted
though that associated CTD symptoms can be very mild,
emphasizing the importance of a thorough clinical history
and examination.
4.2. Hereditary Haemorrhagic Telangiectasia. Hereditary
haemorrhagic telangiectasia (HHT, Rendu-Osler-Weber syn-
drome, OMIM# 187300) is an autosomal dominant vascular
dysplasia described as the triad of mucocutaneous telang-
iectases, recurrent epistaxis or gastrointestinal haemorrhage
and a family history of the disorder (Figure 9) [118]. Visceral
involvement, the fourth clinical criterion, includes that of the
lung, liver and brain [118]. Most patients exhibit symptoms
by the age of 40. The pathogenesis of the arteriovenous
malformations in HHT includes dilatation of postcapillary
venules which enlarge and connect through capillaries
with dilated arterioles. With increase in size, the capillary
segments disappear and an AV communication is formed
[118].
HHT is caused by mutations in the ENG and ALK1
gene (chrom. 9q34.1 and 12q11-q14), encoding endoglin and
Activin A receptor Type II-like 1, respectively, [119, 120].
Other genetic loci for HHT have been reported, indicating
genetic heterogeneity [121]. Endoglin is a TGF-β binding
protein and causes HHT1, which is associated with an earlier
onset of epistaxis and telangiectasias. ALK1-associated HHT
(HHT2), caused by disruption of the Type I cell-surface
receptor for the TGF-β superfamily of ligands, features later
onset and more hepatic involvement compared to HHT1
[120, 121].
Cerebral and spinal complications of HHT include
telangiectases, arteriovenous malformations and carotid-
cavernous fistulas [122]. Moreover, HHT patients are prone
Figure 9: Telangiectasias on the inner side of the lower eyelid in a
HHT patient.
to pulmonary arteriovenous fistulae, responsible for para-
doxical embolism resulting in stroke or transient ischaemic
attack [123]. Cerebral haemorrhage in HHT patients usually
has a devastating eﬀect [122].
The diagnosis of HHT is based on the presence of the
above mentioned criteria and can bemade if at least 3 criteria
are present [118]. Molecular analysis of the ENG and ALK1
genes can confirm the diagnosis and allows familial screening
and counselling. In this respect, it is important to recognize
that children of a patient cannot be reassured of not having
HHT without negative molecular analysis as symptoms most
often only occur in the second or third decade of life.
Molecular testing in such young individuals, who are not able
to give consent, remains however controversial. A similar
controversy exists about the screening of asymptomatic indi-
viduals for cerebral arteriovenous malformations, though it
is recommended in some countries due to the devastating
eﬀects of a cerebral bleeding.
Management of HHT can consist of therapy with beva-
cizumab, an antiVEGF antibody of which several successful
reports were published [124]. Other treatments, including
estrogen or antifibrinolytic therapy, have inconsistent results.
Importantly, all patients should be screened for pulmonary
arteriovenous fistulae. No optimal screening protocol has
been established but should include chest radiography and
contrast echocardiogram. Depending on the results, this can
be complemented with CT scan of the chest or pulmonary
angiography [125, 126].
4.3. Fibromuscular Dysplasia. Fibromuscular dysplasia
(FMD, OMIM# 135580) is an autosomal dominant
noninflammatory, nonatherosclerotic segmental disease of
the arteries, occurring in young to middle-aged individuals
[127]. While renal arteries are most commonly aﬀected,
resulting in hypertension, other large vessels including
carotid and vertebral arteries may be involved [128, 129].
The origin of FMD remains currently largely unknown, with
speculation of a collagen disorder, congenital aetiology and
inflammatory origin. Thus far, no unequivocally associated
genes have been discovered [127].
Stroke Research and Treatment 13
Table 3: Summary of the most important connective tissue diseases related to stroke in young adults.
Disease Inherit. Diagnosis Phenotype
Vascular Ehlers-Danlos
syndrome
AD
Biochemical analysis (skin biopsy)
COL3A1 analysis (fibroblasts)
Facial gestalt (thin nose and lips, sunken cheeks), skin fragility,
extreme vascular fragility, rupture of uterus and colon
Intracerebral aneurysm, carotid/vertebral dissection
Type 4 collagen-related
small vessel disease
AD COL4A1 analysis (blood sample)
Infantile hemiparesis, seizures, migraine, retinal artery
tortuosity, renal and muscular involvement
Small vessel ischaemic stroke or haemorrhage
HANAC syndrome AD
Skin biopsy
COL4A1 analysis (blood sample)
Hereditary angiopathy with retinal artery tortuosity, cystic
renal disease, cerebral aneurysm, muscle cramps
Osteogenesis imperfecta
AD
AR
Radiological examination
Biochemical analysis (skin biopsy)
Molecular analysis of OI genes
(fibroblasts and blood sample)
Fractures, osteopenia, bone deformities, hearing loss, blue
sclerae, dentinogenesis imperfecta
Intracerebral aneurysm, moyamoya-like disease,
carotid/vertebral dissection
AD polycystic kidneys AD
Renal ultrasonography
PKD1/2 linkage analysis (blood)
PKD1/2 molecular analysis (blood)
Bilateral renal cysts, liver and pancreas cysts, aortic
dilatation/dissection
Intracranial aneurysm
Pseudoxanthoma
elasticum
AR
Skin biopsy
ABCC6 analysis (blood sample)
Yellowish skin papules in flexural areas, retinopathy, coronary
and peripheral artery disease
Ischaemic stroke in patients and heterozygous carriers
PXE-like syndrome AR
Coagulation testing
Skin biopsy
GGCX analysis (blood sample)
Generalized cutis laxa, mild retinopathy, coagulation disorder
Cerebral aneurysm?
Marfan syndrome AD
Revised Ghent Nosology
Fibrillin 1 analysis (blood sample)
Tall stature, arachnodactyly, pectus deformity, ectopia lentis,
aortic root dilatation
Carotid artery dissection, cerebral and spinal cord infarction
Loeys-Dietz syndrome
Type I
AD
TGFBR1 and 2 analysis (blood
sample)
Marfanoid habitus, hypertelorism, cleft palate, bifid uvula,
generalized arterial tortuosity and aneurysms
intracranial aneurysm, carotid and vertebral aneurysm
Loeys-Dietz syndrome
Type II
AD
TGFBR1 and 2 analysis (blood
sample)
Vascular EDS-like phenotype, generalized arterial tortuosity
and aneurysms
intracranial aneurysm, carotid and vertebral aneurysm
Bicuspid aortic valve AD
Echocardiography
NOTCH1 gene in familial cases
(blood sample)
Bicuspid aortic valve on ultrasound
Dissection of carotid and cerebral arteries, intracranial aneurysm
Arterial tortuosity
syndrome
AR SLC2A10 analysis (blood sample)
Facial dysmorphism, arachnodactyly, joint and skin laxity,
arterial elongation, tortuosity and aneurysms
Ischaemic stroke?
Supravalvular aortic
stenosis
AD ELN analysis (blood sample)
Left ventricular outflow obstruction
Ischaemic stroke
Williams-Beuren
syndrome
AD FISH or microarray
SVAS, facial dysmorphism, short stature
Ischaemic stroke, intracerebral haemorrhage
Spontaneous cervical
artery dissection
AD Clinical examination
Exclude vascular EDS, Marfan syndrome and osteogenesis
imperfecta
Hereditary
haemorrhagic
telangiectasia
AD
Clinical evaluation
ENG and ALK1 analysis (blood
sample)
Mucocutaneous telangiectases, epistaxis, gastrointestinal
haemorrhage
Cerebral/spinal telangiectases, carotid-carvernous fistulas,
ischaemic stroke or TIA, cerebral haemorrhage
Fibromuscular dysplasia AD
Doppler ultrasound and
angiography
String of beads in aﬀected vascular beds
TIA and ischaemic stroke, cervicocranial dissection, intracerebral
aneurysm
Cerebrovascular phenotypes are indicated in italics. AD: autosomal dominant; AR: autosomal recessive.
Neurological implications of FMD include TIA and
stroke, resulting from occlusion, arterial dissection of cer-
vicocranial vessels or subarachnoid haemorrhage due to
ruptured aneurysm [129–135]. The latter may be more
likely when there is also renal involvement, due to the
hypertension. Particularly the association of haemorrhage
due to aneurysm rupture and ischaemic stroke due to
stenosis in a given patient is characteristic of cerebral FMD.
Diagnosis of FMD is made based on clinical history,
doppler ultrasound and angiography, via which the typical
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image of “string of beads” can be seen [127]. Treatment
may imply either surgical correction with resection of the
diseased vessel portion or stenting by a vascular radiologist.
The success of these treatments depends largely on the early
detection of the disease [127, 136].
5. Candidate Extracellular Matrix Genes
Besides the distinct connective tissue disorders described
above, some ECM proteins playing an essential role in
connective tissue homeostasis have been suggested to be
implicated in haemorrhagic or ischaemic stroke. As the ECM
contains over 2500 proteins, the summary below is not
limitative and several other ECM constituents are likely to be
involved in stroke, either leading to a well-defined phenotype
or as a more general risk factor.
5.1. Stromelysin. Stromelysin-1 or MMP3 is a member of
the matrix metalloproteinase (MMP) family, regulating the
accumulation of ECM. Recently, an association was found in
Italian ischaemic stroke patients who were homozygous for a
common promotor variant (genotype 5A/5A), in which both
alleles have a run of 5 adenosines [137]. This finding was
inconsistent with in vitro studies which showed a promotor
variant with a run of 6 adenosines to be associated with a
higher IMT and warrants further study [138].
5.2. Versican. Versican is a proteoglycan playing an impor-
tant role in ECM assembly. The gene encoding versican,
CSPG2 (chrom. 5q) is located in a genomic region reported
to be associated with intracranial aneurysms. Ruigrok et
al. suggested that SNPs around and in the versican gene
play a role in the susceptibility of intracranial aneurysms,
which was confirmed in a second, larger study [139, 140].
It is currently unclear though to what extent these basepair
changes are causal for the aneurysms.
5.3. Perlecan. Perlecan (heparansulfateproteoglycan) is a
major component of basement membranes, encoded by
the HSPG gene (chrom. 1p36.1). Like versican, it is also
located in a region reported to be associated with intracranial
aneurysms. HSPG SNPs were recently shown to be mildly
associated with intracranial aneurysms; the exact nature of
this pathogenetic link needs to be further clarified [139].
5.4. 92 kDA Type IV Collagenase. 92 kDA Type IV collagenase
or MMP9 is an enzyme, encoded by the MMP9 gene (chrom.
20q11.2–q13.1) that degrades Type IV and V collagens. It
has been shown that collagenolysis plays an important role
in aneurysmal rupture, whereas elastinolysis is pertinent to
vessel dilatation [141]. An MMP9 polymorphism associated
with higher promotor activity has been shown to occur at a
higher frequency in patients with intracranial haemorrhage,
though a second independent study was not able to confirm
this relation [142, 143]. MMP9 has also been implicated
in haemorrhages following intravenous thrombolysis and
haemorrhagic transformation of ischaemic stroke [144].
Further studies are needed to test these associations.
6. Conclusion
The objective of this paper was to bring to attention several
connective tissue disorders which can be related to ischaemic
and/or haemorrhagic stroke in young adults (Table 3).
While some are more prevalent than others, it should be
emphasized that the severity of the clinical spectrum of
many of these disorders is highly variable. This probably
leads to underdiagnosis, a phenomenon which has been
clearly established for some CTD, such as PXE. In this
respect, the importance of a well-oriented clinical history
and examination as well as a good familial history should be
emphasized, as often only the combination of all these data
will raise suspicion of an underlying connective tissue cause.
As many of these disorders have important implications,
in first instance for the patient but also for his relatives,
recognition of CTD as a cause for stroke is no longer an
academic issue but an essential part of the stroke aetiological
evaluation in children and young adults. Though molecular
testing is already available for several of these disorders, it
can be foreseen that many more ECM constituents and other
proteins involved directly or indirectly in connective tissue
homeostasis will be identified as a cause of or risk factor for
stroke in the young.
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